Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)
about
sameAs
Disruption of N-linked glycosylation enhances ubiquitin-mediated proteasomal degradation of the human ATP-binding cassette transporter ABCG2Cancer cell adaptation to chemotherapy.Vaults: a ribonucleoprotein particle involved in drug resistance?Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemiaCharacterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation.Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance.Investigation into the biological properties of the olive polyphenol, hydroxytyrosol: mechanistic insights by genome-wide mRNA-Seq analysis.Molecular pathways: regulation and therapeutic implications of multidrug resistanceBreast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid LeukemiaRepositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceThe challenge of exploiting ABCG2 in the clinic.The MRP family of drug efflux pumps.Progress in defining multidrug resistance in leukemia.Xanthines down-regulate the drug transporter ABCG2 and reverse multidrug resistanceABCG2 expression, function, and promoter methylation in human multiple myelomaGene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction.CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.Discovering natural product modulators to overcome multidrug resistance in cancer chemotherapy.Possibilities for tailored and targeted therapy in paediatric acute myeloid leukaemia.The emerging pharmacotherapeutic significance of the breast cancer resistance protein (ABCG2).Role of the breast cancer resistance protein (ABCG2) in drug transport.The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo.The role of transporters in the toxicity of nucleoside and nucleotide analogs.Unconjugated bilirubin elevation impairs the function and expression of breast cancer resistance protein (BCRP) at the blood-brain barrier in bile duct-ligated ratsEstrogen Enhances the Expression of the Multidrug Transporter Gene ABCG2-Increasing Drug Resistance of Breast Cancer Cells through Estrogen Receptors.Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.Human ABCG2: structure, function, and its role in multidrug resistance.Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics.Andrographolide Suppresses MV4-11 Cell Proliferation through the Inhibition of FLT3 Signaling, Fatty Acid Synthesis and Cellular Iron Uptake.Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivoPrediction of Therapy Response and Prognosis in Leukemias by Flow Cytometric MDR Assays.Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group.Breast cancer resistance protein (BCRP/MXR/ABCG2) in acute myeloid leukemia: discordance between expression and function.Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP.Flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs.Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response.
P2860
Q24316869-8388F783-E690-49E1-82DD-B3E4B432C264Q24811347-27C580C9-A748-495C-B4DC-91C09C0F5879Q28212334-23EC7802-7072-4684-B125-93A127908E51Q30444746-9DB4EBA6-6643-465D-B7E2-2C596759BEC5Q30497200-B82CD35D-0BE0-4BBA-AFFB-F6C248597B54Q33184830-E3091F16-34BA-40C7-A8F8-FD087B50001BQ33763765-E4BEB47D-E826-4932-BC52-A240CC6746F5Q34033276-83084B06-9A18-4DC2-9840-1BFCBF1BD5BBQ34255292-F87BDFA3-8BCF-4FD6-B397-A5B91D65E41CQ34444082-AC227F1B-A2FB-44A7-874F-EF318580AEDCQ34559115-469F5E85-F208-49EC-8FB4-581CF612BA11Q34774854-1659B19C-3E03-4708-8633-D912A46862BBQ34968909-0637A4F1-25D3-4A81-968F-482F9073BDD8Q35567296-4783D7B6-7F23-4394-ABCA-2A56468D82ABQ35680318-BF749ADF-B475-423A-9048-8E4E99D9FFB0Q35776784-ADF5000E-BEE9-4E00-93AF-4D11BD8A3B17Q35848835-72B1E72E-9A66-4141-8A63-C8F2EB964D78Q35848938-AB7FCC65-89F8-409C-91EF-F66D9A0CC39FQ35880840-3AAA492A-8AA1-47C7-B2B1-13B33E7EBC75Q35915497-43370EC4-A57A-4D07-93D7-22E511FC3427Q35921471-330CC5C1-46D4-4944-A3C7-31716699A32DQ36052743-6A9921F0-EC0B-47E2-BFC4-C8FF1995DE82Q36250753-590B697D-822C-4C14-BE90-F939E4207C80Q36358700-F6739CD2-20B0-4DD8-B7F4-D33345C88C62Q36629578-F67958FD-4898-4436-965F-DC007366B87EQ36921993-1A254778-727A-44F7-9D8C-2555C01CE92CQ37151581-A9A1A49A-6332-4B47-8BC2-B12B1DC4454CQ37631633-F11CAEA0-7CAB-4807-90C7-6009FE4C7E4BQ37958162-7EE98AFA-7293-439C-A2AF-EF0E9D6067B1Q38003156-9B90A608-65A4-4EF1-B83C-238612F20A15Q38187646-F414110C-699B-4D75-BE0F-423ABDE134E2Q38693701-43DBB9E7-B391-42BA-8D48-E74BA278EA2CQ38710502-2A4A670A-494E-4BF5-A255-1EAFDB4AA8ADQ39341118-9E0D61F3-5AA2-450C-AA36-8556E56D7994Q40394531-DDCCED31-0BEA-4B99-B499-C1D5B736534CQ40543176-324BB9F9-5D0C-4FF8-A08C-373E236A1502Q40623805-9670E4B9-B2A0-48FD-BFFF-51BF65738140Q41709561-4BCC3B34-E28F-44DB-B2F0-3B85FEF751D3Q42166480-FAF4D676-ECEB-4FFC-BB81-6613234FB191Q46109720-41223FE1-B985-4FE9-9679-8E2F3A66D626
P2860
Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML)
description
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2002
@ast
im Mai 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: May 2002)
@en
vedecký článok (publikovaný 2002-05)
@sk
vědecký článek publikovaný v roce 2002
@cs
wetenschappelijk artikel (gepubliceerd in 2002-05)
@nl
наукова стаття, опублікована в травні 2002
@uk
مقالة علمية (نشرت في مايو 2002)
@ar
name
Increased expression of the br ...... y acute myeloid leukemia (AML)
@ast
Increased expression of the br ...... y acute myeloid leukemia (AML)
@en
Increased expression of the br ...... y acute myeloid leukemia (AML)
@nl
type
label
Increased expression of the br ...... y acute myeloid leukemia (AML)
@ast
Increased expression of the br ...... y acute myeloid leukemia (AML)
@en
Increased expression of the br ...... y acute myeloid leukemia (AML)
@nl
prefLabel
Increased expression of the br ...... y acute myeloid leukemia (AML)
@ast
Increased expression of the br ...... y acute myeloid leukemia (AML)
@en
Increased expression of the br ...... y acute myeloid leukemia (AML)
@nl
P2093
P3181
P356
P1433
P1476
Increased expression of the br ...... y acute myeloid leukemia (AML)
@en
P2093
B van der Holt
M M van den Heuvel-Eibrink
P J M Vossebeld
P Sonneveld
P2888
P304
P3181
P356
10.1038/SJ.LEU.2402496
P407
P577
2002-05-01T00:00:00Z
P5875
P6179
1023164407